Hospital
Frankfort Hospital, INC.
Frankfort Hospital, INC. was paid $39.41M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 99284, emergency room visit (serious) — 24% of everything it billed.
33Billing provider infoFRANKFORT HOSPITAL, INC.
FRANKFORT, KY 40601
FRANKFORT, KY 40601
33aNPI1427095488assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$39.41M
24GClaims647,334
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#15 of 36
Median peer was paid$36.08M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,735 | $6.35M | |
| 2019 | 103,068 | $6.03M | |
| 2020 | 86,163 | $5.13M | |
| 2021 | 88,928 | $5.77M | |
| 2022 | 86,850 | $5.44M | |
| 2023 | 92,496 | $5.60M | |
| 2024incomplete | 79,094 | $5.09M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 37,185 | 29,727 | $9.57M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 19% | 36,140 | 31,026 | $7.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 6,380 | 4,756 | $2.53M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.7% | 24,157 | 18,270 | $2.24M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.2% | 7,961 | 6,442 | $2.04M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 9,568 | 8,671 | $1.38M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.7% | 16,705 | 4,792 | $1.07M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 11,552 | 4,101 | $710K |
| 71045 | Radiologic examination, chest; single view | 1.7% | 19,616 | 14,566 | $668K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.6% | 16,276 | 4,917 | $630K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 6,689 | 5,133 | $628K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 3,906 | 3,018 | $626K |
201 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.2% | 1,701 | $491K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 8,495 | $441K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 2,146 | $428K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 5,990 | $423K |
| G0378 | Hospital observation service, per hour | 1.1% | 2,854 | $418K |
| 80053 | Comprehensive metabolic panel | <1% | 59,062 | $378K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,462 | $373K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,285 | $310K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,972 | $274K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,416 | $270K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,808 | $241K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 17,488 | $232K |
| 85027 | <1% | 48,003 | $214K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,776 | $200K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,406 | $179K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,093 | $157K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,479 | $154K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,985 | $145K |
| 81001 | <1% | 25,223 | $143K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,127 | $135K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,106 | $132K |
| 97162 | <1% | 1,911 | $122K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 815 | $118K |
| 93971 | <1% | 1,245 | $115K | |
| 73630 | <1% | 2,280 | $110K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 182 | $98K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 20,149 | $97K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 132 | $94K |
| 73030 | <1% | 2,215 | $92K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 188 | $89K |
| 73610 | <1% | 2,184 | $84K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,983 | $80K |
| 81025 | <1% | 9,081 | $76K | |
| 80322 | <1% | 2,541 | $74K | |
| 83880 | <1% | 4,652 | $72K | |
| 73130 | <1% | 1,673 | $72K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 231 | $70K |
| 84484 | <1% | 11,086 | $68K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 721 | $65K |
| 73562 | <1% | 1,527 | $65K | |
| 71250 | <1% | 720 | $63K | |
| 72100 | <1% | 1,375 | $62K | |
| 76830 | Ultrasound, transvaginal | <1% | 492 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,968 | $60K |
| 12001 | <1% | 613 | $58K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,086 | $56K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,887 | $52K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 162 | $51K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,370 | $51K |
| 72110 | <1% | 503 | $51K | |
| 88304 | <1% | 655 | $49K | |
| 83690 | <1% | 13,979 | $49K | |
| 73564 | <1% | 845 | $47K | |
| 73110 | <1% | 1,151 | $45K | |
| 74018 | <1% | 1,797 | $45K | |
| 97163 | <1% | 928 | $45K | |
| 72131 | <1% | 576 | $42K | |
| 70496 | <1% | 156 | $40K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,453 | $40K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 455 | $40K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 112 | $39K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,463 | $38K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,356 | $36K |
| 70486 | <1% | 333 | $35K | |
| 87430 | <1% | 4,914 | $34K | |
| 80061 | Lipid panel | <1% | 3,419 | $32K |
| 96376 | <1% | 1,479 | $32K | |
| 70498 | <1% | 175 | $32K | |
| 72170 | <1% | 1,112 | $31K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 678 | $31K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,275 | $29K |
| 73502 | <1% | 598 | $29K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,280 | $29K |
| 85730 | <1% | 2,861 | $29K | |
| 85610 | <1% | 7,396 | $28K | |
| 74019 | <1% | 357 | $27K | |
| 76642 | <1% | 514 | $25K | |
| 83605 | <1% | 4,969 | $25K | |
| 87040 | <1% | 2,652 | $25K | |
| 80076 | <1% | 5,980 | $23K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,969 | $23K |
| 80047 | <1% | 3,669 | $23K | |
| 83735 | <1% | 6,511 | $22K | |
| 84702 | <1% | 2,976 | $22K | |
| 93975 | <1% | 179 | $22K | |
| 80074 | <1% | 589 | $19K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 598 | $19K |
| 92526 | <1% | 379 | $19K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,042 | $19K |
| 97597 | <1% | 405 | $18K | |
| 12011 | <1% | 175 | $18K | |
| 82607 | <1% | 1,470 | $17K | |
| 73590 | <1% | 355 | $16K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 46 | $15K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,622 | $15K |
| 87081 | <1% | 4,449 | $14K | |
| 82728 | <1% | 1,309 | $14K | |
| 84703 | <1% | 3,712 | $14K | |
| 73080 | <1% | 364 | $13K | |
| 97032 | <1% | 447 | $13K | |
| 85378 | <1% | 2,140 | $12K | |
| 72128 | <1% | 208 | $12K | |
| 87077 | <1% | 2,410 | $11K | |
| 82746 | <1% | 959 | $11K | |
| 80331 | <1% | 556 | $11K | |
| 80329 | <1% | 655 | $10K | |
| 82550 | <1% | 2,903 | $10K | |
| 86171 | <1% | 1,900 | $10K | |
| 87186 | <1% | 1,336 | $9K | |
| 82803 | <1% | 853 | $9K | |
| 86850 | <1% | 1,746 | $9K | |
| 83550 | <1% | 1,223 | $9K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 46 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 318 | $9K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 754 | $8K |
| 81000 | <1% | 2,186 | $8K | |
| 83540 | <1% | 1,399 | $7K | |
| 84439 | <1% | 900 | $7K | |
| 94644 | <1% | 332 | $7K | |
| 10060 | <1% | 45 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 160 | $7K |
| 97166 | <1% | 119 | $6K | |
| 43450 | <1% | 34 | $6K | |
| 72040 | <1% | 159 | $6K | |
| 86900 | <1% | 2,791 | $6K | |
| 86901 | <1% | 2,776 | $5K | |
| 73090 | <1% | 171 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 44 | $5K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,559 | $5K |
| 76857 | <1% | 106 | $5K | |
| 78227 | <1% | 40 | $5K | |
| 76770 | <1% | 53 | $5K | |
| 87070 | <1% | 1,023 | $5K | |
| 94060 | <1% | 72 | $5K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 17 | $4K |
| 82553 | <1% | 432 | $3K | |
| 94729 | <1% | 161 | $3K | |
| 81003 | <1% | 488 | $3K | |
| 86701 | <1% | 289 | $3K | |
| 97161 | <1% | 43 | $3K | |
| 86140 | <1% | 849 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 32 | $3K |
| 85651 | <1% | 625 | $2K | |
| 76536 | <1% | 14 | $2K | |
| 87205 | <1% | 467 | $2K | |
| 76870 | <1% | 37 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 256 | $2K |
| 84100 | <1% | 765 | $2K | |
| 71101 | <1% | 48 | $2K | |
| 97167 | <1% | 25 | $2K | |
| C1769 | Guide wire | <1% | 14 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 56 | $2K |
| 82150 | <1% | 291 | $1K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 16 | $1K |
| 73521 | <1% | 17 | $1K | |
| 86308 | <1% | 331 | $1K | |
| 93976 | <1% | 12 | $1K | |
| 94726 | <1% | 40 | $979.95 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 13 | $964.47 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 15 | $948.60 |
| 84550 | <1% | 397 | $928.69 | |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $770.68 |
| 87210 | <1% | 174 | $614.90 | |
| 84425 | <1% | 47 | $452.19 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 37 | $451.87 |
| 82248 | <1% | 237 | $402.35 | |
| 82784 | <1% | 26 | $384.70 | |
| 86593 | <1% | 70 | $346.56 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 17 | $332.85 |
| 29125 | <1% | 15 | $316.15 | |
| 80069 | <1% | 101 | $305.38 | |
| 83516 | <1% | 14 | $269.77 | |
| 88300 | <1% | 12 | $212.23 | |
| 83615 | <1% | 59 | $203.02 | |
| 86255 | <1% | 14 | $198.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 658 | $171.94 |
| 86922 | <1% | 16 | $171.69 | |
| 82272 | <1% | 57 | $149.19 | |
| 87340 | <1% | 14 | $131.80 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 259 | $128.85 |
| 82947 | <1% | 49 | $124.74 | |
| 86706 | <1% | 12 | $115.74 | |
| 93356 | <1% | 242 | $93.62 | |
| 84460 | <1% | 30 | $86.87 | |
| 84132 | <1% | 30 | $61.49 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 413 | $59.60 |
| 82140 | <1% | 15 | $54.15 | |
| 84450 | <1% | 14 | $52.23 | |
| 84156 | <1% | 36 | $45.14 | |
| 82009 | <1% | 15 | $39.38 | |
| 82565 | <1% | 16 | $32.88 | |
| 36600 | <1% | 19 | $31.30 | |
| 85014 | <1% | 21 | $14.22 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 58 | $9.19 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 188 | $3.37 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 51 | $0.73 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15 | $0.18 |
| J2704 | Injection, propofol, 10 mg | 0% | 164 | $0.00 |
| A9270 | Non-covered item or service | 0% | 153 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 18 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 38 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANKINS, SPENCER (CFO)